The IRF8 mRNA levels were much lower in primary APL samples than in normal monocytes or even in neutrophils regardless of whether they were treated with or without ATRA or ATO (Figure 3g), indicating that the ATRA or ATO alone was insufficient to restore the depressed IRF8 level in patient-derived APL cells. This evidence concerns the gene IRF8 and acute promyelocytic leukemia.